抗リウマチ薬の世界市場2020-2039

◆英語タイトル:GLOBAL ANTI-RHEUMATICS MARKET FORECAST 2020-2028
◆商品コード:INK20MY012
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:168
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは抗リウマチ薬の世界市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別(処方薬、市販薬)分析、薬物クラス別(疾患修飾抗リウマチ薬、非ステロイド性抗炎症薬、副腎皮質ホルモン、尿酸薬、その他)分析、地域別分析、企業情報などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・抗リウマチ薬世界市場:種類別(処方薬、市販薬)
・抗リウマチ薬世界市場:薬物クラス別(疾患修飾抗リウマチ薬、非ステロイド性抗炎症薬、副腎皮質ホルモン、尿酸薬、その他)
・地域別分析
・企業情報
【レポートの概要】

KEY FINDINGS
The global anti-rheumatics market is anticipated to record a CAGR of 2.32% during the projected period of 2020-2028. The factors that offer lucrative growth opportunities include a surge in the geriatric population all over the world, an increase in the incidences of obesity, a rise in awareness related to early screening and treatment of rheumatoid arthritis.

MARKET INSIGHTS
Rheumatoid arthritis is a chronic inflammatory medical condition, which causes painful and swollen joints in patients. The drugs used for the treatment of rheumatoid arthritis are called anti-rheumatics. In addition, different types of drugs are used to treat this condition. For example, disease-modifying anti-rheumatics (DMARDs), nonsteroidal anti-inflammatory drugs, corticosteroids, and others. A rapid increase in the geriatric population is one of the significant factors driving the market. The global geriatric population has risen considerably and is vulnerable to rheumatoid arthritis.
Patent expirations are one of the factors restricting the market growth. Patent expirations result in the entry of low-priced generics, which constrains its growth. Moreover, the market is flooded with biologics, which are considered important for the treatment of rheumatoid arthritis. Some are on the verge of patent expiration, and some are no longer exclusive. The patent expiration of popular drugs results in the availability of generics, which are low-prices and impact the revenue generated in the market and hinder the market growth. The competitive rivalry is high in the market, owing to the presence of similar products offered by various players. Disease-modifying anti-rheumatics drugs category in the drug class segment garnered the largest market share in 2019.

REGIONAL INSIGHTS
The global anti-rheumatics market is analyzed geographically on the basis of the markets situated across the regions of North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America holds the largest market share in terms of revenue. This is attributed to the rising geriatric population.

COMPETITIVE INSIGHTS
The market boasts of many prominent players registering their presence in the global market. Some of the major players functioning in the market are Abbott Laboratories, Lupin Ltd, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Novartis International AG, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. RISING GERIATRIC POPULATION ACROSS THE GLOBE
3.2.2. INCREASING OPPORTUNITIES IN THE DEVELOPING ECONOMIES
3.2.3. SURGE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS DISEASE
3.2.4. GROWING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
3.3. KEY RESTRAINTS
3.3.1. PATENT EXPIRATIONS
3.3.2. LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
3.3.3. LESS EXPENSIVE ALTERNATIVES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. ETIOLOGY OF RHEUMATOID ARTHRITIS (RA)
4.3. SYMPTOMS OF RHEUMATOID ARTHRITIS
4.4. RISK FACTORS ASSOCIATED WITH RHEUMATOID ARTHRITIS
4.5. OPPORTUNITY MATRIX
4.6. VENDOR LANDSCAPE
4.7. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. PRESCRIPTION-BASED DRUGS
5.2. OVER-THE-COUNTER DRUGS
6. MARKET BY DRUG CLASS
6.1. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
6.2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
6.3. CORTICOSTEROIDS
6.4. URIC ACID DRUGS
6.5. OTHER DRUG CLASS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UNITED KINGDOM
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. ITALY
7.2.5. RUSSIA
7.2.6. BELGIUM
7.2.7. POLAND
7.2.8. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. JAPAN
7.3.3. INDIA
7.3.4. AUSTRALIA & NEW ZEALAND
7.3.5. SOUTH KOREA
7.3.6. THAILAND
7.3.7. INDONESIA
7.3.8. VIETNAM
7.3.9. REST OF ASIA PACIFIC
7.4. REST OF WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST & AFRICA
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AMGEN INC
8.4. BECTON, DICKINSON & COMPANY (BD)
8.5. BIO-RAD LABORATORIES INC
8.6. BRISTOL-MYERS SQUIBB COMPANY
8.7. ELI LILLY & COMPANY
8.8. LUPIN LIMITED
8.9. F. HOFFMANN-LA ROCHE
8.10. JOHNSON & JOHNSON
8.11. MERCK & CO INC
8.12. NOVARTIS AG
8.13. PERKINELMER
8.14. PFIZER INC
8.15. UCB



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗リウマチ薬の世界市場2020-2039]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆